MOREPENLAB2026-01-012026-03-31MOREPENLAB2026-03-31MOREPENLAB2025-03-31MOREPENLAB2025-04-012026-03-31MOREPENLAB2026-01-012026-03-31in-capmkt:OtherExpenses1MemberMOREPENLAB2026-01-012026-03-31in-capmkt:OtherExpenses2MemberMOREPENLAB2026-01-012026-03-31in-capmkt:OtherExpenses3MemberMOREPENLAB2026-01-012026-03-31in-capmkt:OtherExpenses4MemberMOREPENLAB2025-04-012026-03-31in-capmkt:OtherExpenses1MemberMOREPENLAB2025-04-012026-03-31in-capmkt:OtherExpenses2MemberMOREPENLAB2025-04-012026-03-31in-capmkt:OtherExpenses3MemberMOREPENLAB2025-04-012026-03-31in-capmkt:OtherExpenses4MemberMOREPENLAB2026-03-31OtherNoncurrentFinancialAssetsDomain1MOREPENLAB2026-03-31OtherNoncurrentAssetsDomain1MOREPENLAB2026-03-31OtherCurrentFinancialAssetsDomain1MOREPENLAB2026-03-31OtherCurrentAssetsDomain1MOREPENLAB2026-03-31OtherNoncurrentFinancialLiabilitiesDomain1MOREPENLAB2026-03-31OtherNoncurrentFinancialLiabilitiesDomain2MOREPENLAB2026-03-31OtherCurrentFinancialLiabilitiesDomain1MOREPENLAB2026-03-31OtherCurrentFinancialLiabilitiesDomain2MOREPENLAB2026-03-31OtherCurrentLiabilitiesDomain1MOREPENLAB2026-01-012026-03-31ItemsThatWillNotBeReclassifiedToProfitAndLoss1MOREPENLAB2026-01-012026-03-31ItemsThatWillNotBeReclassifiedToProfitAndLoss2MOREPENLAB2026-01-012026-03-31ItemsThatWillNotBeReclassifiedToProfitAndLoss3MOREPENLAB2025-04-012026-03-31ItemsThatWillNotBeReclassifiedToProfitAndLoss1MOREPENLAB2025-04-012026-03-31ItemsThatWillNotBeReclassifiedToProfitAndLoss2MOREPENLAB2025-04-012026-03-31ItemsThatWillNotBeReclassifiedToProfitAndLoss3MOREPENLAB2026-01-012026-03-31ItemsThatWillBeReclassifiedToProfitAndLoss1MOREPENLAB2025-04-012026-03-31ItemsThatWillBeReclassifiedToProfitAndLoss1MOREPENLAB2026-01-012026-03-31AuditorDomain1iso4217:INRiso4217:INRxbrli:shares500288MOREPENLABNOTLISTEDINE083A01026MOREPEN LABORATORIES LIMITEDMain BoardEquity2025-04-012026-03-312026-05-262026-05-15INRLakhsQuarterlyFourth quarterSingle segmentPharmaceuticals2026-05-2615:00:002026-05-2617:15:00trueCash Flow IndirectDeclaration of unmodified opinion2026-01-012026-03-31AuditedConsolidated48471590008463700049317960002905754000176705000-871930005875570003876600057470000101986200046989210002328750000232875000-889700084763000758660000157009000000437000157446000636310002210770000000109584100020.280.28000.280.281.The above results have been reviewed by the Audit Committee and approved by the Board of Directors at their meeting held on May 26, 2026. The statutory Auditors have carried out the Audit for the year ended March 31, 2026. <BR> <BR> 2.The consolidated basic and diluted earnings per share for the year, after excluding the impact of the aforesaid exceptional item amounting to Rs. 2582.54 Lacs, is at Rs. 1.32 per equity share. <BR> <BR> 3.The Board of Directors at their meeting held on 26th May, 2026 recommended a final dividend of Rs. 0.20/- per share, for the financial year ending March 31, 2026. Final dividend proposed by the Board of Directors is recognized upon approval by the members shareholders, at the forthcoming Annual General Meeting, who have the right to decrease but not increase the amount of dividend recommended by the Board of Directors. <BR> <BR> No dividend shall be payable in respect of 50,62,872 equity shares that had been surrendered by members (erstwhile fixed deposit holders) to the Company for cancellation and had claimed refund of their fixed deposit dues in lieu thereof, in accordance with the order passed by the Hon'ble National Company Law Tribunal (NCLT), Chandigarh, dated March 12, 2018. These shares have been cancelled by the Board of Directors of the Company and are pending for cancellation by the Stock Exchanges. <BR> <BR> 4.'The Government of India has enacted four Labour Codes, namely the Code on Wages, 2019, the Industrial Relations Code, 2020, the Code on Social Security, 2020 and the Occupational Safety, Health and Working Conditions Code, 2020, to consolidate and rationalise existing labour laws. However, the detailed rules and effective dates for implementation of key provisions are yet to be notified. In accordance with Ind AS 19, employee benefit obligations are measured based on laws that are enforceable as at the reporting date. As the relevant provisions of the Labour Codes are not yet operational, the company has continued with the existing accounting treatment at this stage. Accordingly, gratuity and leave encashment continue to be accounted for under the applicable laws. The impact, if any, will be evaluated when the relevant provisions become effective. <BR> <BR> 5.'The Company is engaged in the Pharmaceutical Business Segment. <BR> <BR> 2025-04-012026-03-31AuditedConsolidated180569150002131410001827005600010431057000824605000-2149700023273940001641370003643470003239067000173291100009409460002582540001199200000157972000847630002427350000956465000000-7697000948768000618910001010659000000010958410002113685460001.731.73001.731.73Power and Fuel121899000Travelling Expenses62373000Selling and Distribution Expenses349081000Other Expenses486509000Power and Fuel448972000Travelling Expenses233275000Selling and Distribution Expenses989760000Other Expenses1567060000381160300021551400001318435000010128670008300007554400010892410001290267000772506000027182630002287320003331375000311897000376365000455100015975500044126750004505203000116361410001936120100010958410001136854600012464387000651100012470898000133600600000074298000141030400041239000016458800001987282000610899000288860003143494000317238000044225900042255380003810950002963880004903021000689030300019361201000Other non-current financial assets75544000Other non-current assets1290267000Other current financial assets159755000Other current assets4505203000Other current financial liabilities31690000Lease Liabilities42608000Other current financial liabilities353220000Lease Liabilities89039000Other current liabilities381095000164137000175646000-5012400000-926309000-109590000000-24729500029734400003643470009000071952000000-20000000000-76970000-6199860005792140000002527940000326420000306459000000000008552330004874320000075019500000000001054000043316300000000000-123416000000000000131781800016407400056803000108579000164137000014975200097397700066237000066237000245660000311897000Fair value changes on Equity Instruments through OCI70983000Re-measurement (gain)/loss on Defined Benefit Plans495000Income tax relating to items that will not be reclassified to profit or loss-996600061512000Fair value changes on Equity Instruments through OCI70983000Re-measurement (gain)/loss on Defined Benefit Plans969000Income tax relating to items that will not be reclassified to profit or loss-100590006189300000Exchange Difference on trasnlation of foreign operations21190002119000Exchange Difference on trasnlation of foreign operations-2000-2000006363100061891000AuditedtrueS P Babuta & Associatestrue2028-06-30